Bayer HealthCare and Kyoto University’s Office of Society-Academia Collaboration for Innovation pharma partners by signing a two-year agreement to jointly identify candidates for possible collaborative research projects.
The pharma partners will focus on key areas of unmet medical need such as cardiology, oncology, hematology, gynecology, and ophthalmology.
Bayer said the agreement is part of its overall approach to collaborate with external partners from academia and industry to discover and develop new treatment options.
The agreement with KU-SACI aims to combine Kyoto’s innovative approaches in diverse research areas with Bayer’s expertise in drug discovery and development.
The endeavor will be supported by Bayer’s newly established Open Innovation Center Japan in Osaka.
For further deal information visit Current Agreements (subscription required)
Read: more on Bayer partnering deals, insights, M&A article
Report: Partnering Agreements with Bayer 2009-2014
Report: Top 50 Big Biotech Partnering and M&A Deal Trends
View: Partnering Scorecard in CP Insight– view top life science partnering deals by value
View: DealMetrics in CP Insight – the latest deal trend infographics for life science deal making
View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: CP Insight’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity